During the recent session, Virax Biolabs Group Ltd (NASDAQ:VRAX)’s traded shares were 0.68 million, with the beta value of the company hitting 1.67. At the last check today, the stock’s price was $2.45, reflecting an intraday gain of 10.86% or $0.24. The 52-week high for the VRAX share is $9.00, that puts it down -267.35 from that peak though still a striking 75.51% gain since the share price plummeted to a 52-week low of $0.60. The company’s market capitalization is $10.63M, and the average intraday trading volume over the past 10 days was 0.88 million shares, and the average trade volume was 1.79 million shares over the past three months.

Virax Biolabs Group Ltd (NASDAQ:VRAX) trade information

Virax Biolabs Group Ltd (VRAX) registered a 10.86% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.86% in intraday trading to $2.45, hitting a weekly high. The stock’s 5-day price performance is 41.62%, and it has moved by 31.72% in 30 days. Based on these gigs, the overall price performance for the year is 89.19%. The short interest in Virax Biolabs Group Ltd (NASDAQ:VRAX) is 0.45 million shares and it means that shorts have 0.11 day(s) to cover. An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -52.25%.

VRAX Dividends

Virax Biolabs Group Ltd is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Virax Biolabs Group Ltd (NASDAQ:VRAX)’s Major holders

The next largest institutional holding, with 25672.0 shares, is of HRT FINANCIAL LP’s that is approximately 1.2795% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $29000.0.